Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II)
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Background: Patients with major depressive disorder (MDD) having active suicidal ideation with intent require immediate treatment. Methods: This double-blind study (ASPIRE II) randomized adults (aged 18–64 years) with MDD having active suicidal ideation with intent to esketamine 84 mg or placebo nasal spray twice weekly for 4 weeks, given with comprehensive standard of care (hospitalization ≥5 days and newly initiated or optimized oral antidepressant[s]). Change from baseline to 24 hours post-first dose in Montgomery-Asberg Depression Rating Scale total score (primary efficacy endpoint) was analyzed using ANCOVA. Clinical Global Impression–Severity of Suicidality–revised (key secondary endpoint) was analyzed using ANCOVA on ranks of change. Results: Of 230 patients who were randomized (115 per arm), 227 received study drug and were included in efficacy/safety analyses; 184 (80.0%) completed double-blind treatment. Greater improvement in Montgomery-Asberg Depression Rating Scale total score was observed with esketamine (mean [SD]: –15.7 [11.56]) vs placebo (–12.4 [10.43]), each with standard of care, at 24 hours (least-squares mean difference [SE]: –3.9 [1.39], 95% CI: –6.60, –1.11; 2-sided P = .006). This was also noted at the earlier (4-hour) timepoint (least-squares mean difference –4.2, 95% CI: –6.38, –1.94). Patients in both treatment groups experienced rapid reduction in Clinical Global Impression–Severity of Suicidality–revised score; the between-group difference was not statistically significant. The most common adverse events among esketamine-treated patients were dizziness, dissociation, nausea, dysgeusia, somnolence, headache, and paresthesia. Conclusion: This study confirmed rapid and robust reduction of depressive symptoms with esketamine nasal spray in severely ill patients with MDD who have active suicidal ideation with intent. Trial Registration: Clinical Trials.gov identifier: NCT03097133
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2. Least-square mean changes (±SE) from baseline for Montgomery-Asberg Depression Rating Scale (MADRS) total score during the double-blind treatment phase (mixed-effects model using repeated measures [MMRM]; observed cases). aIncludes patients who had their dose reduced due to tolerability issues. Note: Negative change in score indicates improvement.](https://figures.cochat.ai/paper-figures/867338dabcaf42aca05b1ca83661094a/esketamine-nasal-spray-for-rapid-reduction-of-depressive-symptoms-in-patients-figure-2.jpg)


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“With regard to esketamine in particular, clinical use was largely based on four positive Phase 3 efficacy studies [62][63][64][65] that informed the subsequent FDA approval of intranasal esketamine for TRD and suicidal ideation with intent, as described above.”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [64]
The cited source says what the claim attributes to it.
In the citing paper
“a nasal spray form of S-ketamine was approved by the Food and Drug Administration (FDA) in the USA and by the European Medicines Agency (EMA) in Europe in 2019 [18].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States
Hasin, D. S., Sarvet, A. L., Meyers, J. L., Saha, T. D., Ruan, W. J., Stohl, M., & Grant, B. F. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.4602 · Cited by 1,737
Synaptic Dysfunction in Depression: Potential Therapeutic Targets
Duman, R. S., & Aghajanian, G. K. (2012) · Science · doi:10.1126/science.1222939 · Cited by 1,651
Risk factors for suicide in psychiatric outpatients: A 20-year prospective study.
Brown, G. K., Beck, A. T., Steer, R. A., & Grisham, J. R. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.68.3.371 · Cited by 1,317 · cited 1×
“Nearly all patients with MDD who attempt or complete suicide have suicidal ideation prior to the event (Brown et al., 2000; Sokero et al., 2003).”
BackgroundValidity and Reliability of the Observer??s: Assessment of Alertness/Sedation Scale
CHERNIK, D. A., GILLINGS, D., LAINE, H., HENDLER, J., SILVER, J. M., DAVIDSON, A. B., SCHWAM, E. M., & SIEGEL, J. L. (1990) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199008000-00003 · Cited by 1,246
Bremner, J. D., Krystal, J. H., Putnam, F. W., Southwick, S. M., Marmar, C., Charney, D. S., & Mazure, C. M. (1998) · Journal of Traumatic Stress · doi:10.1023/a:1024465317902 · Cited by 817
Canuso, C. M., Singh, J. B., Fedgchin, M., Alphs, L., Lane, R., Lim, P., Pinter, C., Hough, D., Sanacora, G., Manji, H., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.17060720 · Cited by 676
Self-citationWilliams, J. B. W., & Kobak, K. A. (2008) · British Journal of Psychiatry · doi:10.1192/bjp.bp.106.032532 · Cited by 463 · cited 1×
“Eligible patients were between 18 and 64 years of age, met the Diagnostic and Statistical Manual of Mental Disorders–5th edition (DSM-5) criteria (American Psychiatric Association, 2013) for MDD (without psychosis) based on diagnostic assessment with the Mini International Neuropsychiatric Interview, and had a MADRS (…”
MethodPractice Guideline for the Assessment and Treatment of Patients With Suicidal Behaviors
(2007) · APA Practice Guidelines for the Treatment of Psychiatric Disorders: Comprehensive Guidelines and Guideline Watches · doi:10.1176/appi.books.9780890423363.56008 · Cited by 406
The European Psychiatric Association (EPA) guidance on suicide treatment and prevention
Wasserman, D., Rihmer, Z., Rujescu, D., Sarchiapone, M., Sokolowski, M., Titelman, D., Zalsman, G., Zemishlany, Z., & Carli, V. (2012) · European Psychiatry · doi:10.1016/j.eurpsy.2011.06.003 · Cited by 390 · cited 3×
“Current standard of care includes initiation or optimization of oral antidepressants and, frequently, hospitalization (American Psychiatric Association, 2003; Wasserman et al., 2012).”
Background
Research works printed but not linked: 1
- Spravato (esketamine) nasal spray. Prescribing information. 2020. Janssen Pharmaceutical Companies.
Cited by
Items 101–200 of 418
Age, Dose, and Locomotion: Decoding Vulnerability to Ketamine in C57BL/6J and BALB/c Mice
Chen, W.-C., Wang, T., Chang, F., Chen, P., & Chen, Y.-C. (2023) · Biomedicines · doi:10.3390/biomedicines11071821 · Cited by 17
Xiao, L., Zhang, Z., Lu, J., Liu, Z., Zhang, J., Kang, L., Tang, J., & Zou, X. (2024) · BMC Anesthesiology · doi:10.1186/s12871-024-02779-0 · Cited by 11
“Previous studies have shown that deep sedation with subanaesthetic doses of esketamine and propofol can maintain haemodynamic stability during painless gastrointestinal endoscopy [27], painless abortion [14], and bronchoscopy [28], consistent with the findings of this study.”
ResultEsketamine–A quick-acting novel antidepressant without the disadvantages of ketamine
Shoib, S., Kotra, M., Javed, S., Nguyen, V.-S., & Malathesh, B. C. (2022) · Hormone Molecular Biology and Clinical Investigation · doi:10.1515/hmbci-2021-0099 · Cited by 13
Floriano, I., Silvinato, A., & Bernardo, W. M. (2023) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.2023d694 · Cited by 12
Downregulated NPAS4 in multiple brain regions is associated with major depressive disorder
Selçuk, B., Aksu, T., Dereli, O., & Adebalı, O. (2023) · Scientific Reports · doi:10.1038/s41598-023-48646-9 · Cited by 12
Anti-Suicidal Effects of Lithium, Ketamine, and Clozapine—A 10-Year Systematic Review
Waszak, P. M., Opalko, J., Olszańska, N., & Zagożdżon, P. (2025) · Pharmaceuticals · doi:10.3390/ph18050742 · Cited by 15
“Similarly to Ionescu et al., TP-Su et al. noted that individuals whose current depressive episode lasted >24 months or who failed >4 antidepressant treatments did not benefit from ketamine’s anti-suicidal effects [51,53,56].”
Kitay, B. M., Murphy, E., Macaluso, M., Corlett, P. R., Hershenberg, R., Joormann, J., Martinez‐Kaigi, V., Nikayin, S., Rhee, T. G., Sanacora, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115585 · Cited by 13
What clinicians need to know about intranasal esketamine for treatment-resistant depression?
Hope, J., Copolov, D., Tiller, J. W. G., Galbally, M., Hopwood, M., Newton, R., & Keks, N. A. (2023) · Australasian Psychiatry · doi:10.1177/10398562231211171 · Cited by 12
Li, C., Shi, J., Wei, S., & Jia, H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01511-x · Cited by 10
“In addition to their analgesic effect [11], ketamine and esketamine have recently been reported to have potential antidepressant [12] and antitumor properties [13, 14] but underlying mechanisms remain unknown.”
BackgroundDeng, Q., Parker, E., Wu, C., Zhu, L., Liu, T. C., Duan, R., & Yang, L. (2024) · Aging and Disease · doi:10.14336/ad.2024.0239 · Cited by 12
“Notedly, the heightened risk of suicide among depressed individuals is commonly attributable to the delayed onset of antidepressant effectiveness [16].”
Alves-Pereira, R., Fontes, M., Cordeiro, V., Bandeira, I. D., Faria-Guimarães, D., Silva, S. S., Mello, R. P., Leal, G. C.-G., Sampaio, A. S., & Quarantini, L. C. (2024) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000578 · Cited by 9
Chepke, C., Shelton, R. C., Sanacora, G., Doherty, T., Tsytsik, P., & Parker, N. (2024) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyae058 · Cited by 12
“…clinically relevant; therefore, they were not reported as adverse events (AEs) by the investigators in the majority of cases (Daly et al., 2019; Fedgchin et al., 2019; Popova et al., 2019; Fu et al., 2020; Ionescu et al., 2020; Ochs-Ross et al., 2020; Wajs et al., 2020; Reif et al., 2023).”
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Wang, Z., Jiang, L., Ma, W., Li, X., Gao, Q., Lian, S., & Yu, W. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3555 · Cited by 15
“15,16 Furthermore, there exists inconsistency across the study outcomes from these existing RCTs. 13,14,17 Although an existing meta-analysis summarized current clinical evidence and indicated a favorable effect of intranasal esketamine administration in MDD, 18 it did not provide detailed…”
Ketamine in Clinical Practice: Transitioning from Anesthetic Agent to Psychiatric Therapeutic
Quintero, J.-M., Bustos, R., Lechtig, S., Beltran, S., & Zarate, C. A. (2025) · Cambridge University Press eBooks · doi:10.1017/9781009585330.007 · Cited by 13
Synaptic priming: A framework for pharmacotherapy in depression
Brown, K. A., Ajibola, M. I., Medeiros, G. C., & Gould, T. D. (2025) · Neuron · doi:10.1016/j.neuron.2025.09.010 · Cited by 13
Nguyen, T. M. L., Jollant, F., Tritschler, L., Colle, R., Corruble, E., & Gardier, A. M. (2023) · Pharmaceuticals · doi:10.3390/ph16040634 · Cited by 11
“Recently, two clinical trials demonstrated the rapid and robust efficacy of an esketamine nasal spray in reducing depressive symptoms in severely ill patients with major depressive disorder who were having active suicidal ideation with intent [172,173].”
Bloomfield-Clagett, B., Ballard, E. D., Greenstein, D. K., Wilkinson, S. T., Grunebaum, M. F., Murrough, J. W., Mathew, S. J., Phillips, J. L., Fava, M., Sanacora, G., et al. (2022) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyac055 · Cited by 8
d’Andrea, G., Miuli, A., Pettorruso, M., Cavallotto, C., Marrangone, C., Cocco, A., Filippis, S. D., Martiadis, V., Andriola, I., Barlati, S., et al. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.09.004 · Cited by 12
Raffone, F., Mazzoni, F., Ciechi, A. D., Girone, N., Macellaro, M., Martinotti, G., Dell’Osso, B. M., Olivola, M., & Martiadis, V. (2026) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2026.104983 · Cited by 10
Chee, K. Y., Muhdi, N., Ali, N. H., Amir, N., Bernardo, C., Chan, L. F., Ho, R., Ittasakul, P., Kwansanit, P., Mariano, M. P. V., et al. (2022) · BMC Psychiatry · doi:10.1186/s12888-022-04140-6 · Cited by 10
“Patients with MDD with active suicidal ideation with intent who received intranasal esketamine and comprehensive standard of care achieved clinically meaningful and statistically significant improvement in depressive symptoms at 24 hours post-treatment compared with placebo and comprehensive standard of care; patients…”
MethodCorral, R. M., Giraldo, E. B., Cetkovich, M., Córdoba, R., Chestaro, J., Gama, C. S., Bonetto, G. G., López‐Jaramillo, C., Moreno, R. A., Ng, B., et al. (2023) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.sjpmh.2023.06.001 · Cited by 11
Making Progress in Clinical Trials for Suicide Prevention: A Review
Wilkinson, S. T., Bryan, C. J., Alphs, L. D., Canuso, C. M., Ostacher, M. J., Price, R. B., Bloch, M. H., Zarate, C. A., & Rhee, T. G. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2024.4810 · Cited by 7
Self-citationSpravato for Treatment-Resistant Depression: Efficacy and Sexual Side Effect Profile
Raza, A. A., Ahmed, G., Zafar, H., Akhtar, S. O., Mobin, M. B., & Samadi, A. (2025) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s548944 · Cited by 6
“45,46 Additionally, pooled analyses from multiple phase 3 trials have reported remission rates ranging from 27% to 50%, with notable onset of action as early as 24 hours after the first dose.”
Psychiatric and legal considerations for ketamine treatment within prison settings
Bayrhammer-Savel, M., Ortner, M., Hout, M. C. V., & Komorowski, A. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1316108 · Cited by 9
Rethinking the medication management of major depression
Mann, J. J., & Rizk, M. (2023) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2023.2190886 · Cited by 10
Intramuscular Ketamine to Treat Major Depressive Disorder: A Case Series of Forty Patients
Bonnett, C. J., Jain, R., Ross, C. N., Wallington, D. A., & Schock, T. R. (2021) · Journal of Psychiatry and Mental Health · doi:10.16966/2474-7769.145 · Cited by 9
Pompili, M., Trocchia, M. A., Longhini, L., Dispenza, E., Legge, C. D., Sarubbi, S., Erbuto, D., & Berardelli, I. (2025) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.70008 · Cited by 8
Molecular Mechanisms of Depression: The Interplay Between Genes and Receptors
Oatu, A., Trifu, S. C., & Coman, E. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311325 · Cited by 10
“The intranasal S-enantiomer esketamine translates these rapid plasticity effects clinically: the ASPIRE phase-3 trials showed clinically meaningful reductions in depressive symptoms and suicidal ideation within 24 h of the first dose, maintained with twice-weekly administration [208].”
Wang, Y., Xu, J., Zhou, X., Che, L., Qiu, M., Liu, Y., Gao, M., & Yang, Z. (2025) · Advanced Science · doi:10.1002/advs.202516024 · Cited by 13
Ketamine-assisted psychotherapies for mental disorders: A historical overview and systematic review
Veraart, J. K. E., Schimmers, N., Breeksema, J. J., Seybert, C., Kamphuis, J., Huber, L. F. T., Rota, A., Coerts, D. T., Oliveira-Maia, A. J., & Schoevers, R. A. (2026) · Clinical Psychology Review · doi:10.1016/j.cpr.2026.102706 · Cited by 9
A synopsis of multitarget therapeutic effects of anesthetics on depression
Wu, G., & Xu, H. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176032 · Cited by 7
Perspectives in treatment-resistant depression: esketamine and electroconvulsive therapy
Baldinger, P., Spies, M., Bozic, I., Kasper, S. F., Rujescu, D., & Frey, R. (2024) · Wiener klinische Wochenschrift · doi:10.1007/s00508-024-02358-w · Cited by 9
Self-citationRozjabek, H., Li, N., Hartmann, H., Fu, D., Canuso, C. M., & Jamieson, C. (2022) · Journal of Patient-Reported Outcomes · doi:10.1186/s41687-022-00453-y · Cited by 11
“Methods and primary data of these studies have been reported earlier [32, 33].”
BackgroundSelf-citationBartova, L., Fugger, G., Dold, M., Kautzky, A., Fanelli, G., Zanardi, R., Albani, D., Weidenauer, A., Rujescu, D., Souery, D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.068 · Cited by 7
Self-citationEsketamine enhances memory reconsolidation in the novel object recognition task
Li, H., Ying, L., Wan, F., Shiqiao, K., Yijie, F., Chuli, X., Xudong, Y., Xinhong, Y., & Zhiyong, X. (2024) · Physiology & Behavior · doi:10.1016/j.physbeh.2024.114461 · Cited by 6
Gutiérrez, G., Rosenblat, J. D., Hawken, E. R., Swainson, J., & Vázquez, G. H. (2022) · JMIR Research Protocols · doi:10.2196/34711 · Cited by 7
Turkoz, I., Lopena, O. J., Salvadore, G., Sanacora, G., Shelton, R. C., & Fu, D. (2022) · CNS Spectrums · doi:10.1017/s1092852922000931 · Cited by 11
Self-citationLi, J., Ma, L., Sun, H., Li, M., Cao, Y., Peng, Y., & Xu, J. (2025) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01920-x · Cited by 5
“Eight trials were included in the meta-analysis, and the other 5 studies [ 39, 41, 44, 48, 49 ] were only included in the qualitative analysis because their data were not available.”
Hossein, S., Rengasamy, M. L., Uzamere, A., Spotts, C., Howland, R. H., Wallace, M. L., Mathew, S. J., & Price, R. B. (2025) · The British Journal of Psychiatry · doi:10.1192/bjp.2024.276 · Cited by 9
“9,10,36 Given potential floor effects in our study (e.g. if baseline suicidal ideation scores had been higher, rapid differences between ketamine and saline might have been detected), future RCTs examining patients with higher baseline levels of suicidal ideation would be beneficial; only ∼ 25% of…”
Chen, X., Zhou, R., Lan, L., Zhu, L., Chen, C., Zhang, X., Han, J., & Xia, L. (2024) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s463028 · Cited by 5
Smith, K. E., Feldman, J. D., Freinberg, C., Shade, S., & Grundmann, O. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00640-z · Cited by 6
“The sodium salt of tianeptine is prescribed in South America, Asia, and Europe as a monotherapy or combination therapy for psychiatric treatment [6–8], typically for depressive, anxiety, and stressor-related disorders [2].”
Pharmacological Strategies for Suicide Prevention Based on the Social Pain Model: A Scoping Review
Rajkumar, R. P. (2022) · Psych · doi:10.3390/psych4030038 · Cited by 5
Pompili, M., Dell’Osso, B. M., Rosso, G., Amore, M., Bellomo, A., Mautone, A., Pilotto, E., Ramacciotti, S., Scardigli, M. I., Ascione, G., et al. (2023) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2023.152430 · Cited by 5
Ketamine for Major Depressive Disorder
Costi, S. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_453 · Cited by 6
Harding, L., Joshi, K., Zhdanava, M., Shah, A., Voegel, A., Chen, C., & Pilon, D. (2024) · Drugs - Real World Outcomes · doi:10.1007/s40801-024-00425-2 · Cited by 6
“In addition, given its rapid onset, esketamine has also shown some benefit during psychiatric emergencies in patients with MDD, including TRD and MDD with suicidal ideation, where treatment options are currently limited [4, 9, 10].”
BackgroundLiu, R., Liu, C., Feng, D., Guo, T., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1414703 · Cited by 7
Feng, R., Wang, Z., Yang, Y., Wang, Q., Zhao, Y., Qian, X., & Qian, J. (2026) · Journal of Anesthesia · doi:10.1007/s00540-026-03853-2 · Cited by 4
Sajid, S., Mann, J. J., & Grunebaum, M. F. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03255-0 · Cited by 10
“The other three reports were from the two Janssen Inc. phase 3 trials of IN S-ketamine for MDD with acute SI [49 – 51 Fig.”
Pharmacokinetics and brain distribution of ketamine after nasal administration
Yang, Z., Li, L., Deng, B., Xu, Y., Du, Y., Lv, Y., & Zhai, X. (2025) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2025.116945 · Cited by 5
Huang, C., Hu, L., Wu, L., Geng, F., Wong, G. T. C., Zhang, Y., Reif, A., Bao, Y., Xue, Q., & Lü, L. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-03320-6 · Cited by 17
Advances in the assessment and study of suicide in late-life depression
Xu, T., Mao, Y., Wang, Y., Zhang, W., Cao, H., & Yu, E. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1610730 · Cited by 5
Chan, E. C., Wallace, K., Yang, E. H., Roper, L., Aryal, G., Lodhi, R. J., Isenberg, R., Carnes, P. J., Baskys, A., Green, B., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114316 · Cited by 6
Lewitzka, U., Anjo, J., Annus, T., Borentain, S., Hope, K., Major, A., O’Hara, M., & Pompili, M. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.05.099 · Cited by 5
Pros and cons of esketamine treatment in psychiatry
Gutiérrez, G., & Vázquez, G. H. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.003 · Cited by 5
Sato, A., Sugawara, N., Kawamata, Y., & Yasui‐Furukori, N. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12428 · Cited by 4
Bahji, A., Vázquez, G. H., & Zarate, C. A. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.12.069 · Cited by 5
“Given the recent publication of additional esketamine trials for suicidality and major depression (Fu et al., 2020; Ionescu et al., 2020), we are currently working on an updated meta-analysis.”
BackgroundNöhles, V. B., Bermpohl, F., Falkai, P., Reif-Leonhard, C., Jessen, F., Adli, M., Otte, C., Meyer‐Lindenberg, A., Bauer, M., Rubarth, K., et al. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-05230-9 · Cited by 5
Sleep alterations in treatment-resistant depression patients undergoing ketamine treatment
Kwaśny, A., Cubała, W. J., Włodarczyk, A., & Pastuszak, K. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00641-1 · Cited by 4
Tavares, V. D. D. O., Gonçalves, K. T. D. C., Barros, M. L. D. M., de Brito, A. J. C., Cavalcanti-Ribeiro, P., Palhano-Fontes, F., Falchi-Carvalho, M., Nunes, E. A., Sarris, J. J., Perkins, D., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001946 · Cited by 5
Ketamine for unipolar depression: A systematic review of efficacy and safety
Peiris, T. E., Pokhrel, A., & Paudel, Y. (2025) · Australasian Psychiatry · doi:10.1177/10398562251328805 · Cited by 3
“47 Additionally, research has shown that ketamine may provide superior ef fi cacy in reducing depression scores during ECTcomparedtoagents like sodium thiopental.”
Al-Garni, A. M., Vázquez, G. H., Alotibi, T., Hernandorena, C. V., & Knyahnytska, Y. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120475 · Cited by 8
Is there an independant anti-suicidal effect of esketamine in treatment resistant depression?
Danon, M., Ostronoff, G., Petit, A., de Maricourt, P., Kopeć, J. M., Mékaoui, L., Berkovitch, L., & Gorwood, P. A. P. M. (2026) · Journal of Affective Disorders · doi:10.1016/j.jad.2026.121181 · Cited by 3
Ketamine pharmacotherapy for major depressive disorder: A narrative review
Miller, C. H., Hickman, A., Baten, C., Ali, Z., Kahlon, S. K., Klassen, A. M., Zamora, G., Shepherd, J. H., Venegas, G., Miller, J. A., et al. (2026) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2026.111651 · Cited by 3
Alphs, L. D., Fu, D., Williamson, D., Jamieson, C., Greist, J. H., Harrington, M. A., Lindenmayer, J., McCullumsmith, C. B., Sheehan, D. V., Shelton, R. C., et al. (2022) · PubMed Central · Cited by 7
Self-citationNew pharmacotherapies to tackle the unmet needs in bipolar disorder: a focus on acute suicidality
Kotzalidis, G. D., Fiaschè, F., Alcibiade, A., Monti, L., Segni, F. D., Mazza, M., & Sani, G. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2334425 · Cited by 4
“However, even that study did not provide details about the assessment of the SIBAT [67].”
BackgroundMethodSantucci, M. C., Katz, R. B., Pittman, B. P., Nikayin, S., & Wilkinson, S. T. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06896-7 · Cited by 3
Consistency of the Antidepressant Effect of Intranasal Esketamine in Phase 3 Clinical Trials
Preskorn, S. (2021) · Journal of Psychiatric Practice · doi:10.1097/pra.0000000000000531 · Cited by 3
Xu, P., & Sun, Y. (2022) · Medicine · doi:10.1097/md.0000000000029713 · Cited by 7
“workers.[14] At present, the status and influencing factors of suicide attempts in patients of this subtype remains unclear.”
BackgroundVoelker, J., Sheehan, J. J., Le, H. H., Toro‐Díaz, H., Li, S., & Joshi, K. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0226 · Cited by 5
Drug Discovery in Psychiatry: Rethinking Conventional Wisdom
Ghaemi, S. N. (2022) · The Canadian Journal of Psychiatry · doi:10.1177/07067437221112907 · Cited by 3
“Yet these claims remain limited to acute symptomatic benefit, not long-term disease modification.(15)”
BackgroundAssessing suicide risk in chronic pain management: a narrative review across drug classes
Brezić, N., Gligorevic, S., Candido, K. D., & Knežević, N. N. (2024) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2024.2391999 · Cited by 2
“RCTs indicate that esketamine nasal spray rapidly and effectively alleviates depressive symptoms in patients with MDD who exhibit active suicidal ideation with intent, particularly in those with a history of suicide attempts [169,170].”
Expanding Ketamine Application for Treatment of Acute Suicidality in Long-Duration Spaceflight
Kutz, C. J., Mistry, A. M., & Dukes, C. H. (2025) · Aerospace Medicine and Human Performance · doi:10.3357/amhp.6619.2025 · Cited by 3
Canuso, C. M., Bossie, C. A., Fu, D., Lane, R., Doherty, T., Lignugaris, A., Fagiolini, A. M., Llorca, P., McIntyre, R. S., Reif, A., et al. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20250250 · Cited by 2
Self-citationXia, L., Wu, N., Wang, D., Zhou, H., & Zhang, X. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03784-8 · Cited by 5
Leonardi, M., Frediani, A., Angeletti, M. C., Biseo, M., Versaci, G., Castiglioni, M., Olivola, M., Vismara, M. E. M., Varinelli, A., Bosi, M. F., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010250 · Cited by 4
“By contrast, between-group differences in the CGI-SS-r were not statistically significant, although suicidality was reduced in both arms [15,16].”
Liu, T.-H., Shen, H.-S., Wu, J., Huang, P., Shih, Y.-J., & Lai, C.-C. (2026) · Translational Psychiatry · doi:10.1038/s41398-026-04032-3 · Cited by 2
Schüle, C., Sobieraj, A., & Rogg, H. V. (2026) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/a-2742-4611 · Cited by 3
An Update on Somatic Treatments for Suicide Risk
Rizk, M., & Mann, J. J. (2026) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20260287 · Cited by 4
Chan, E. C., Wallace, K., Yang, E. H., Roper, L., Aryal, G., Lodhi, R. J., Baskys, A., Isenberg, R., Carnes, P. J., Green, B., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.114128 · Cited by 3
“The structure of the SIBAT has been detailed elsewhere and the SIBAT has been used in a phase 3 program for evaluating the efficacy and safety of a rapid acting antidepressant (Fu et al., 2020; Ionescu et al., 2021).”
MethodCompleted suicides and intranasal esketamine therapy: A case report and case series
Rayburn, W. F., & Albright, B. B. (2023) · Psychiatry Research Case Reports · doi:10.1016/j.psycr.2023.100104 · Cited by 7
Sahay, S., Lundh, A. E., Sirole, R. P., McCullumsmith, R. E., & O'Donovan, S. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051826 · Cited by 3
“For example, esketamine has been approved by the United States Food and Drug Administration (FDA) for individuals with major depressive disorder (MDD) who have acute, active suicidal ideation with intent [3].”
Chen, B. K., Jin, M., Turi, G. F., Luna, V. M., Shah, A., Moniz, T., Shannon, M. E., Pauers, M. M., Williams, B. L., Pham, V., et al. (2025) · Biological Psychiatry · doi:10.1016/j.biopsych.2025.09.011 · Cited by 2
Stahl, S. M. (2020) · Cambridge University Press eBooks · doi:10.1017/9781108921275.024 · Cited by 2
Borentain, S., Desai, P., Fu, D., Chen, L. N., Lane, R., Mathews, M., & Canuso, C. M. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221123046 · Cited by 7
“In the ASPIRE studies of MDD and active suicidal ideation with intent (Fu et al., 2020; Ionescu et al., 2021), patients in both the esketamine plus standard-of-care and placebo plus standard-of-care groups experienced rapid reduction in the severity of their suicidality, as measured by Clinical Global Impression—Sever…”
BackgroundMethodInfluentialSelf-citationSuicide and psychiatric disorders
Berardelli, I., Rogante, E., Lamis, D. A., & Pompili, M. (2024) · Oxford University Press eBooks · doi:10.1093/med/9780198843405.003.0018 · Cited by 2
Vieira, F., Caliman‐Fontes, A. T., Souza‐Marques, B., Faria-Guimarães, D., Lins-Silva, D. H., Santos‐Lima, C., Jesus‐Nunes, A. P., & Quarantini, L. C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116443 · Cited by 1
Zhang, L., Bao, D., & Wang, C. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116490 · Cited by 1
Beyond surgery: Repurposing anesthetics for treatment of central nervous system disorders
Mielko, J., Pakulska, J., Oszczyk, A., Lustyk, K., Pytka, K., & Sałaciak, K. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111386 · Cited by 1
Chen, B. K., Hunsberger, H. C., Whye, A., Matthews, L. C., Yook, A., Willner, M. J., Logan, R. W., Johns, S., Weisblum, E., & Denny, C. A. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01804-9 · Cited by 3
Tianeptine Products: Public Health Threat or Niche Substance use?
Smith, K. E., Hill, K., Bergeria, C. L., & Strickland, J. C. (2025) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2025.2570939 · Cited by 2
Fountoulakis, K. Ν., Tatsiopoulou, P., Saitis, A., Fountoulakis, N. K., & Schatzberg, A. F. (2025) · European Child & Adolescent Psychiatry · doi:10.1007/s00787-025-02897-1 · Cited by 4
“Concerning suicidality, it seems that the data are positive at 2–4 h (2/2), equivocal at 24 h (1/4), and negative at week 4 (0/6) [9, 10, 12, 23, 26, 27, 32, 52, 62, 70, 73].”
Masdrakis, V. G., Tebbs, Z., Natsis, V., & Baldwin, D. S. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811251389583 · Cited by 4
“The TRANSFORM studies (comprising “TRANSFORM-1”; Fedgchin et al., 2019], and “TRANSFORM-2”; Popova et al., 2019, studies) and the ASPIRE studies (comprising ASPIRE-I; Fu et al., 2020, and ASPIRE-II; Ionescu et al., 2021, studies) were the approval studies by Johnson & Johnson®.”
InfluentialQutishat, M., Al‐Huseini, S., & Albalushi, M. (2026) · International Journal of Mental Health · doi:10.1080/00207411.2025.2610783 · Cited by 1
Advances in antidepressant pharmacotherapy: phase 3 evidence and clinical perspectives
Cuomo, A., Pinzi, M., & Fagiolini, A. M. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2634195 · Cited by 1
“Clinical Global Impression – Severity (CGI-S) scores improved in both groups, though no significant between-group differences were noted for this measure [46,49,50].”
García-Jiménez, J., Núñez-Arias, D., Merelo, G. C., Miller, A., Romero, A. M., Gutiérrez-Rojas, L., & Mesones-Peral, J. E. (2026) · Journal of Psychopharmacology · doi:10.1177/02698811261430495 · Cited by 1
Clinical applications of esketamine: Current status and future perspectives
Li, H., Deng, J., Liu, T., & Zhang, Y. (2026) · Journal of International Medical Research · doi:10.1177/03000605261432759 · Cited by 2
Esketamine Nasal Spray: Mechanism of Action, Clinical, and Translational Science
van Hoogdalem, M. W., Fu, D., Drevets, W. C., & Zannikos, P. (2026) · Clinical and Translational Science · doi:10.1111/cts.70527 · Cited by 2
Self-citationPompili, M., Sarubbi, S., Biase, G. D., Roberto, P., Fascetti, W., Trocchia, M. A., Erbuto, D., & Berardelli, I. (2026) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2026.09.005 · Cited by 1
Kowalski, L., Delanogare, E., & de Oliveira, T. B. (2021) · VITTALLE - Revista de Ciências da Saúde · doi:10.14295/vittalle.v33i3.13224 · Cited by 7
“(70) Controlado, paralelo, randomizado e duplo-cego.”
InfluentialCetkovich, M., Abadi, A. F., Camino, S., Bonetto, G. G., Herbst, L., Marengo, E., Torrente, F. M., Maresca, T., Bustin, J., Morra, C. A., et al. (2023) · Vertex Revista Argentina de Psiquiatría · doi:10.53680/vertex.v34i161.488 · Cited by 2
“Sin embargo, en los cuatro ensayos que sustentan su aprobación, padecer TB ha sido utilizado como criterio de exclusión (Popova et al., 2019; Daly et al., 2019; Fu et al., 2020; Ionescu et al., 2021).”
Background
Metadata
- Authors
- Ionescu, D. F., Fu, D.-J., Qiu, X., Lane, R., Lim, P., Kasper, S., Hough, D., Drevets, W. C., Manji, H., & Canuso, C. M.
- Affiliations
- Department of Neuroscience, Janssen Research and Development, LLC, San Diego, CA
- Janssen Research & Development (United States) (US)
- Medical University of Vienna (AT)
- Corresponding author
- Ionescu, Dawn F
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2020-08-29
- Volume
- 24
- Issue
- 1
- Pages
- 22-31
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC7816667
- OpenAlex
- W3082490768
- Cited by
- 418
- References
- 28
- Citations by year
- 2026: 37 · 2025: 55 · 2024: 41 · 2023: 49 · 2022: 43 · 2021: 31 · 2020: 161
- FWCI
- 42.55
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
- Keywords
- esketamine, nasal spray, major depressive disorder, rapid-acting antidepressants, depressive symptoms, suicidality, hospitalization, adverse events, dissociation
- MeSH terms
- Administration, Intranasal, Adolescent, Adult, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Female, Humans, Ketamine, Male, Middle Aged, Outcome Assessment, Health Care, Young Adult, Suicidal Ideation, Nasal Sprays, Patient Acuity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.